Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00008164 | Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia | unknown | Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00451711 | Intermittent Liposomal Amphotericin B Primary Prophylaxis | unknown | Phase 2 | 60 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01488344 | Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 140 | University Hospital MuensterOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00003827 | Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome | unknown | Phase 2 | 25 | ALZAINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00003885 | Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma | unknown | Phase 2 | 60 | Our Lady of Mercy Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01887561 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | unknown | Phase 2 | 100 | Kanto CML Study GroupOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT01503502 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
| NCT01809392 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 2 / Phase 3 | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT01037556 | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | unknown | Phase 1 / Phase 2 | 50 | Proacta, IncorporatedINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00838240 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia(AML-14A) | unknown | Phase 1 / Phase 2 | 114 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 20, 2012 | clinicaltrials |
| NCT01627132 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | unknown | Phase 2 | 50 | Shimousa Hematology Study GroupOTHER | 1 | Jun 25, 2012 | clinicaltrials |
| NCT00111345 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | unknown | Phase 2 / Phase 3 | 550 | University Hospital MuensterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00887042 | Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | unknown | Phase 1 / Phase 2 | 35 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Mar 26, 2012 | clinicaltrials |
| NCT01556477 | The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | unknown | Phase 2 | 72 | Nordic MDS GroupNETWORK | 1 | Mar 16, 2012 | clinicaltrials |
| NCT01534702 | Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML(CIARA) | unknown | Phase 1 / Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01180426 | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 30 | Chroma TherapeuticsINDUSTRY | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia(ASCI) | unknown | Phase 1 / Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01509300 | HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors | unknown | Phase 1 / Phase 2 | 10 | Asan Medical CenterOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00866762 | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | unknown | Phase 2 | 60 | Copenhagen University Hospital at HerlevOTHER | 4 | Dec 12, 2011 | clinicaltrials |
| NCT01423175 | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS(ClAraC-SCT) | unknown | Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT01066494 | A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 20 | Antisoma ResearchINDUSTRY | 2 | Jan 17, 2011 | clinicaltrials |
| NCT01220544 | Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells | unknown | Phase 1 / Phase 2 | 30 | Charite University, Berlin, GermanyOTHER | 1 | Oct 14, 2010 | clinicaltrials |
| NCT01133886 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure(DEC-MDS) | unknown | Phase 2 | 50 | King's College LondonOTHER | 1 | Sep 3, 2010 | clinicaltrials |
| NCT01146977 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)(CBF(+)AML) | unknown | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 22, 2010 | clinicaltrials |
| NCT01039363 | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Dec 25, 2009 | clinicaltrials |
| NCT00276926 | Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias | unknown | Phase 2 | — | University of BolognaOTHER | 1 | Sep 15, 2009 | clinicaltrials |
| NCT00966810 | Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | unknown | Phase 2 / Phase 3 | 40 | Rambam Health Care CampusOTHER | 1 | Aug 27, 2009 | clinicaltrials |
| NCT00510939 | Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia(HEMOS AML 0106) | unknown | Phase 2 | 72 | University of BolognaOTHER | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00466843 | Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome | unknown | Phase 2 | 54 | Office of Rare Diseases (ORD)NIH | 1 | Jun 2, 2009 | clinicaltrials |
| NCT00003681 | Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | unknown | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | May 12, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00146913 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00153582 | WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 25 | Charite University, Berlin, GermanyOTHER | 1 | Feb 22, 2006 | clinicaltrials |
| NCT00209833 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | unknown | Phase 2 / Phase 3 | 200 | Hannover Medical SchoolOTHER | 1 | Nov 18, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2013source: clinicaltrials